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Summary.-Twenty-four patients with advanced cancer not reacting to conventional
therapy were treated with 97 courses of i.v. MER (methanol extraction residue of
BCG). MER was administered by i.v. infusion over a 4-h period, twice a week, in
dosages varying from 0-05 mg to 1 25 mg. The skin reactivity to 5 recall antigens was
evaluated in the patients. All patients except 4 were anergic. Twelve patients had no
side-effects. Anergic patients had less side-effects than ergic patients. The side-
effects recorded in the others were fever, chills, vomiting and tachycardia. The
reaction subsided within 24 h after treatment and was tolerable for most patients.
In 2 patients an objective improvement was observed. No changes in cutaneous
reactivity, renal and hepatic functions were found. A significant increase in peripheral
leucocyte count was noted in two patients and slight a increase in the remainder.
ANIMAL studies showed that i.v. BCGin-
hibited tumour growth after i.v. injection
of tumour material (Baldwin and Pimm,
1973) and lung metastasis after surgical
removal ofan s.c. transplant (Morton etal.,
1971). It is not known whether the i.v.
route ofadministration ofimmunotherapy
is more effective than intradermal (i.d.) or
s.c. routes, although theoretically it could
be more effective. This stimulated interest
in giving various immunostimulators such
as BCG or C. parvum i.v. to cancer
patients. Such Phase I studies have
recently been reported, with some evi-
dence of tumour regression (Band et al.,
1975; Israel et al., 1975, Muggleton,
Prince and Hilton, 1975).
MER is the methanol extraction residue
ofBCG. It has the advantage over BCG of
being a non-viable vaccine. Previously, we
have reported that i.d. injection of MER
improved skin reactivity and the lympho-
cyte in vitro response to various antigens
(Robinson et al., 1975, 1977). In the
present study we have evaluated tolerance
to i.v. injection of MER in different
dosages and its effects on skin reactivity
to recall antigens in advanced cancer
patients.
MATERIALS AND METHODS
Patients.-Twenty-four patients with histo-
logically confirmed malignant neoplasms with
generalized metastases were included in the
study. Table I shows the diagnoses of the
patients. Most patients had epithelial
tumours. There were 15 females and 9 males.
The age of the patients ranged between 28
and 73 years, with a median of 49 and a
mean of 52 years.
The patients had been treated previously
by surgery, radiotherapy and chemotherapy.
MER was recommended in advanced stages
of the disease, when further oncological
treatment was not available. Twelve patients
were on steroid therapy.
The performance status (Karnofsky scale)
was higher than 7 in 3 patients, between
5 and 6 in 5 patients and less than 4 in 16
patients (Table II).
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TABLE I.-Patients,
Patient
number
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
their Age, Sex, Site of Tumour, Previous Treatment and Additional
Treatment during MER Administration
Additional
treatment
Tumour Previous during MER
Age Sex site treatment administration
50
55
30
60
52
55
45
53
45
53
57
28
63
44
42
68
40
50
73
73
46
63
59
59
S = Surgery.
F
M
M
M
M
F
F
F
F
F
F
M
M
F
F
M
F
M
F
F
F
M
F
F
Breast
Oesophagus
Tongue
Lung
Lung
Breast
Ovary
Colon
Hodgkin's
Vagina
Ovary
Testis
Bladder
Unknown
Lung
Stomach
Breast
Lung
Ovary
Rectum
Pancreas
Colon
Colon
Colon
SRC
RC
RC
C
C
SRC
SRC
SC
RC
R
SC
SC
SR
C
C
R
RC
C
C
SR
SC
SC
SC
SC
R = Radiation. C = Chemotherapy.
St
St
StC
St
St
St
St
StC
StC
St
StR
St
St
St= Steroids.
MER injection protocol.-MER/BCG
(Phipps strain supplied by Division ofCancer
Treatment, NCI, NIH) in glucose 50o
solution was given i.v. for a 3-4-h period
twice weekly. One patient received 0 02 mg
MER by i.v. injection, with resulting severe
toxicity. In consequence, MER was given
by i.v. infusions only.
The first 7 patients received doses increas-
ing from 0.01 mg to 0 05 mg of MER for up
to 5 courses per patient. No toxicity was
observed, and 2 other patients received
0 05 mg MER with a later dose of 0 5 mg by
infusion. No severe side-effects were recorded
at this higher dose. Therefore, the next 15
patients were infused with the higher dose of
MER. The highest dose ofMER administered
was 1 5 mg. A total of 97 treatments were
given to the 24 patients. The number of
treatments and dosage per patient are given
in Table II. Eleven patients received more
than 5 courses of MER, 8 of whom received
doses of 0-5 mg or more of MER. Tables II
and III show that 17 patients received 67
courses of0 5 mg or more. Only 27 treatments
had doses below 0 05 mg.
Test antigens.-The patients were tested
by i.d. injection of0(1 ml of 5 recall antigen
preparations. The antigens were purified
protein derivative (PPD 2 TU, Ministry of
Health, Israel), Streptokinase Streptodornase
(Lederle, USA, 40U/10U), Candida 0.1%
(Institute of Biology, Ness Ziona), Mixed
bacteria (0-1% of a mixed suspension of
staphylococcus and streptococcus, Institute
of Biology, Ness Ziona, Israel) and Tricho-
phyton (0.1%, Institute of Biology, Ness
Ziona).
The tests were performed simultaneously
on the forearm of the patients. The average
of 2 diameters of induration at 48 h was
recorded in mm. A negative reaction was
defined as no erythema or induration; a weak
response, erythema and induration <5 mm;
a positive response, induration >5 mm.
Clinical and laboratory investigations.-
All patients receiving i.v. MER were hospital-
ized so that they could be more carefully
observed. Prior to MER infusion, clinical
examination, chest X-ray and the following
laboratory tests were performed: CBC
urinalysis, liver-functiontests (bloodbilirubin,
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TABLE II.- The Number of Treatments, and Dosage per Patient, with Reactions, Survival
after MER and Skin Test Responses
Patient Karnofsky
ntumber scale
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
2
3
5
7
4
3
2
3
3
8
3
3
6
5
3
5-6
4
3
4
3
6
7
4
4
No.
courses
MER
4
1
5
5
1
5
1
7
5
3
4
2
6
3
5
6
3
3
4
4
5
6
3
6
Initial dose Total dose
MER (mg) MER (mg)
0-01
0 04
0 04
0 04
0 04
0-02
0 05
0 05
0 05
0 5
0*5
0 5
0*5
0 5
0*5
0 5
0*5
0 5
1.0
0 5
1*25
1 00
1 00
1 .00
0 07
0 04
0-23
0-24
0 04
0-18
0*05
3-60
1*60
0-85
3 00
1 50
3 00
1.50
2-00
3 00
1 50
1 50
4 00
2-00
6-25
6-50
3 00
7 70
Survival
after MER
Reactions termination
3 days
M 3 weeks
2 weeks
- Alive
3 weeks
M 4 weeks
4 days
3 weeks
M* 2 weeks
S Alive
S Alive
3 days
- Alive
S 6 weeks
S 8 weeks
Alive
M I day
1 day
1 week
Iweek
M 4 weeks
M* 12 weeks
M 3 weeks
M 4 weeks
* Objective improvement.
Al = Moderate. S = Strong.
transaminases), and alkaline phosphatase,
Ca, P, serum urea creatinine and uric acid
levels. Other X-rays and liver and bone
scans were performed when indicated.
After completion of each i.v. treatment,
temperature, pulse and blood pressure were
monitored and subjective evaluation was
made. The presence or absence of chills was
specifically noted each time. Temperatures
above 37 6°C were considered a febrile
response, and a pulse change of20% or more
defined as a tachycardic response.
RESULTS
Subjective and objective evaluation
Five patients displayed subjective im-
provement during and after MER therapy.
One patient stopped taking analgesics and
narcotics during infusions and another
showed improvement in appetite and
general wellbeing.
Objective improvement was noticed in
2 patients. One patient suffered from
TABLE III. Side-effects of MER Treatment
No. with symptoms:
Total
Dose No. of
(mg) treatments
C--
Fever
11 %
Chills
n %
Tachycar
n
Vomiting and
dia malaise
Y. n %
27
3
38
29
8
3
18
9
29-6
47-3
31 0
97 38 39 1
2
3
9
3
7-4 15 55.5
3
23-9 19 50.0
10-3 8 27-6
17 17-5 45 46-4
Skin
test
responses
-F
+
<0 05
0-25
0*5
>1
Trotal
23
2
3
4
3
7-4
10-5
10 3
12 12-3E. ROBINSON, A. BARTAL, J. HONIGMAN AND Y. COHEN
Hodgkin's disease Stage IV with huge
abdominal masses. Prior treatment in-
cluded radiotherapy and chemotherapy of
MOPP and then ABVD. No further treat-
ment could be given due to thrombocyto-
penia and leucopenia. The abdominal
mass was reduced by 50o of its previous
diameter after 4 courses of MER of 0 05
mg increasing to 0 5 mg. The patient
died, however, 2 weeks after finishing
MER treatment. The family refused a
post-mortem examination.
The second patient had lunig metastasis
from colon adenocarcinoma, which
appeared during adjuvant 5-fluorouracil
treatment. No steroid treatment was
introduced. After 6 MER courses a 50°Oh
reduction in the size ofthe lung metastases
was observed on chest X-ray. This
patient had also a subjective improvement
and was alive 3 weeks after finishing the
treatment.
Temperature
A febrile response was noted after 38/97
treatments (39.10) (Table III). Fever
was more frequent after the higher dosage
treatments (470) than after the lower
dosage (29%)0 It is ofinterest to note that
fever occurred after 31 % of the 1-mg
courses, which is similar to the occurrence
after low dosage.
No temperature rise was noted in 5
patients. The fever lasted 24 h in 14
patients and 48 h in 4 patients. In only
one patient, who was treated at the
beginning of the study by an i.v. injection
of 0-02 mg MER, did the febrile response
last 72 h. There was no temperature rise
in 7 patients after the first and second
infusion but it appeared later on. Eight
patients had an opposite pattern of
response, with a febrile reaction initiallv
which subsided with subsequent courses
with change in dose. Four patients showedl
temperature rise after all the treatments.
The highest temperature recorded was
39.5°C and was noted after both a low
and a high dose infusion.
Intake of steroids did not genlerally
influence the appearance of febrile
response. Thus, of 46 courses ofMER given
with no steroid treatment, febrile reaction
occurred after 21 courses (45.60%) whereas
of 49 courses given with corticosteroid
therapy, fever was recorded after 22
courses (43.1 0%). However, it is of interest
to note that 3/4 patients with a strong
febrile reaction were not on steroids.
Tachycardia
Tachycardic response was recorded after
45/97 courses (46.40%). The reaction occur-
red both after the low and high doses of
MER (Table IV). 'IThe highest pulse rate
recorded was 140/min. The pulse regained
its previous range within 24-48 h.
TABLE LIV. Dose and Severity of Side-
effects in the 24 Patients Treated with i.v.
MER
Dose (rng)
Low (Y=(0-05)
High (->005)
Total
No.
None Aild( Severe patients
5 2 0 7
7 6 4 17
Blood pressure
Chan-ges in blood pressure were seldom
encountered in patients after therapy. It
was seen to decrease in only 4 patients
but in no case did the systolic pressure
drop below 70 mmHg. The blood pressure
was found to rise transiently in 2 patients.
Overall toxicity
Table IV shows the overall estimated
toxicity in patients with i.v. MER treat-
ment. Twelve patients had Ino side-effects,
8 patients were recorded as having
tolerable side-effects and only 4 patients
had severe side-effects. These comprised
chills, fever, vomiting, nausea, muscle
pains and headache. All of these patients
received MER in doses of 0-5 mg. Three
of the patients, as noted before, with a
slightly positive skin test had more
marked side-effects. The 2 patients show-
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ing partial remission of 5000 had febrile
responses and a moderate reaction.
Cutaneous reactivity
Twenty of the patients who entered
this study were anergic to 5 recall antigens.
Four patients showed a weak response to
the antigens tested. This was due to the
advanced stage of disease, low perform-
ance status and previous radio-chemo-
therapy. Of the 4 patients who showed
slight reactivity, 3 had febrile responses
associated with chills and vomiting. Two
of the 4 patients were on steroids. Ofthe 2
patients with a 50%/ partial response, one
had a weak response to the recall antigens
and the other wasergic. The skin reactivity
of the patients did not change after i.v.
MER.
Laboratory examination
No major abnormalities occurred in
kidney or liver function. The following
changes were most probably due to pro-
gression of the disease in a patient with
pancreatic tumour: serum bilirubin con-
centration increased from 341 to 5-1 mg
and the serum transaminase concentration
increased from 23 to 76 mg. In another
patient, the alkaline phosphatase level fell
from 7 6 to 3 7 Bessy Laury units. In most
patients a slight increase in the number
of leucocytes was found, and in 2 patients
this was more marked. It increased from
3300 to 14,600 leucocytes per mm3 in one
and from 11,000 to 22,000 leucocytes per
mm3 in the other.
DISCUSSION
Immunotherapy is usually given i.d. or
intratumorally. Recently, Corynebacterium
parvum has been shown to be more
effective when given i.v. (Band et al.,
1975; Cheng et al., 1976; Fisher et al.,
1976; Israel et al., 1975). BCG has also
been given i.v., but as BCG i.d. has
produced fever, malaise, hepatic dys-
function and jaundice, and as there are
reports of disseminated BCG infections,
there are dangers with its i.v. administra-
tion (Bast et al., 1974; Mansell and
Krementz, 1973; Pinsky, Hirsthaut and
Oettgen, 1972; Sparks et al., 1973). No
such side-effects were described with the
non-viable MER vaccine. MER has been
found to be a potent immunostimulator
when given i.d. (Robinson etal., 1975, 1977)
but has never been'given i.v. If MER could
be administered i.v. this could be of
benefit to the patients by avoiding the
skin reaction at the site of MER injec-
tions. Preliminary investigations showed
that mice tolerated i.v. MER injections
well. The present study has shown that
MER can be administered i.v. safely to
patients with advanced cancer and gener-
ally poor condition. The reactions recorded
were tolerable in most patients.
It remains, of course, to be proved that
the i.v. route stimulates the cutaneous
immune response. In the present study
this was not found. We attributed this
possibly to the advanced condition of the
patients' disease. The dose administered
to ergic patients has to be carefully
monitored for possible reactions. Moertel
et al. (1975) have shown objective im-
provement in patients with advanced
gastro-intestinal cancer by i.d. MER
injection. It is of interest that in the
present study objective improvement was
observed in 2 patients.
It is our purpose to continue with MER
i.v. therapy in patients with disease not
reactive to the conventional treatments,
in order to see whether further objective
improvement can be obtained.
This work was supported in part by a
donation in memory of the late Luise
Guterman, administered by the Office of
the Administrator General, Ministry of
Justice and the Medical Research Fund
under the sponsorship of the Ministry of
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